Enhancing Internalization & Synergy with Biparatopic Antibodies in HER2-Positive Cancer
2:30 pm - Wednesday 25th February 2026
- Improving tumor cell uptake to deliver more effective radiation and therapy
- Combining antibodies against distinct HER2 domains to maximize therapeutic impact
- Expanding treatment options for patients with HER2-positive cancers through additive benefits
New Company for 2026
